Bausch Health Companies Inc. (BHC) News
Follow Bausch Health Companies Inc. (BHC) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Bausch Health Hits 52-Week High After Quarterly Earnings
Bausch Health reached $11.89, a 52-week high. Its quarterly earnings were $1.77 per share, compared with the Zacks consensus estimate of $1.08 and $1.16 a year earlier.
EQUITY | Oct 29, 2026, 03:11 PM UTC
M
Bausch Health Shares Surge 21% on Third-Quarter Beat, Higher Guidance
Bausch Health shares rose 21% after third-quarter profit topped expectations, supported by sales growth for its flagship gastrointestinal drug. The company upgraded its full-year guidance.
EARNINGS | Oct 29, 2026, 02:33 PM UTC
M
Bausch Health Reports Third-Quarter Revenue of $2.94 Billion
Bausch Health reported third-quarter 2026 net income of $436 million and diluted EPS of $1.15. Revenue rose 9.7% from a year earlier, with growth across all segments led by Salix and Bausch + Lomb.
EQUITY | Oct 29, 2026, 10:12 AM UTC
M
Bausch Health Q3 Adjusted Earnings and Revenue Rise
Bausch Health reported higher adjusted earnings and revenue for Q3. Its shares were up before the bell.
EQUITY | Oct 29, 2026, 08:26 AM UTC
M
Bausch Health Expects Fiscal 2026 Revenue of $10.98B-$11.18B
Bausch Health now expects fiscal 2026 revenue of $10.98 billion to $11.18 billion, versus a FactSet estimate of $10.96 billion.
EARNINGS | Oct 28, 2026, 09:39 PM UTC
L
Bausch Health Reports Results for Quarter Ended September 30
EARNINGS | Oct 28, 2026, 09:37 PM UTC
M
Bausch Health Posts Q3 Adjusted EPS of $1.77
Bausch Health reported Q3 adjusted EPS of $1.77, versus the FactSet estimate of $1.27.
EARNINGS | Oct 28, 2026, 09:31 PM UTC
M
Bausch Health Sees 2026 Revenue of $10.975B-$11.175B
EARNINGS | Oct 28, 2026, 08:05 PM UTC
M
Bausch Health Reports Third-Quarter Results, Raises Guidance
Bausch Health announced its third-quarter 2026 financial results and raised guidance.
EQUITY | Oct 28, 2026, 08:02 PM UTC
M
S&P/TSX Composite Index Edges Higher in Choppy Trade
The index moved slightly higher as technology and energy sectors advanced.
EQUITY | Oct 28, 2026, 02:39 PM UTC
M
Bausch + Lomb Beats Q3 Adjusted EPS Estimates, Raises FY Outlook
EARNINGS | Oct 28, 2026, 11:40 AM UTC
M
Bausch Health expected to post earnings of $1.25 a share
An earnings preview says Bausch Health Companies Inc. is expected to report earnings of $1.25 per share.
EQUITY | Oct 26, 2026, 08:24 PM UTC
M
Bausch + Lomb Shares Fall Nearly 10% After Interim CEO Appointment
Bausch + Lomb appointed Thomas J. Appio interim CEO, effective immediately, replacing Brent Saunders, as the shares fell nearly 10% Monday. The company and parent Bausch Health said they expect to raise full-year 2026 ad
EQUITY | Oct 12, 2026, 06:13 PM UTC
H
Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D
Preliminary Update on 2026 Guidance2 Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The companies
LIVE | Oct 12, 2026, 10:48 AM UTC
H
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Shares of Tempest Therapeutics Inc (NASDAQ: TPST ) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnolo
LIVE | Sep 16, 2026, 09:04 AM UTC
L
Bausch Health and Yun Lee expand strategic collaboration in Mexico, EMEA
Bausch Health Companies and Yun Lee Marine Group Holdings Ltd said they are expanding their strategic collaboration in Mexico and the EMEA markets.
EQUITY | Sep 08, 2026, 12:13 PM UTC
L
BHC - Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
BHC - Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
EQUITY | Sep 08, 2026, 12:02 PM UTC
L
Bausch Health and YUN expand Mexico and additional EMEA skincare markets
Bausch Health and YUN said their collaboration will expand access to science-led, microbiome-friendly skincare solutions in Mexico and add new EMEA markets, including launches in the Czech Republic, Slovakia, Ukraine, Bu
GEOPOLITICS | Sep 08, 2026, 12:01 PM UTC
L
Bausch Health reports new real-world research on enVista Aspire
Bausch + Lomb said it has published new research on real-world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs).
EQUITY | Sep 02, 2026, 11:00 AM UTC
L
Bausch Health announces Fraxel FTX availability in Australia
Bausch Health said Solta Medical’s Fraxel FTX is now available in Australia.
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap a
EQUITY | Sep 01, 2026, 10:58 AM UTC
L
Bausch Health announces Fraxel FTX availability in Australia
Bausch Health said Solta Medical’s Fraxel FTX® is now available in Australia.
EQUITY | Aug 31, 2026, 10:00 PM UTC
L
BHC - Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
BHC - Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
EQUITY | Aug 27, 2026, 12:02 PM UTC
L
BHC - Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
BHC - Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
EQUITY | Aug 17, 2026, 12:00 PM UTC
L
Bausch Health Companies Raises FY2026 Sales Guidance from $10.670B-$10.920B to $10.790B-$11.040B vs $10.773B Est
Bausch Health Companies (TSX: BHC ) raises FY2026 sales outlook from $10.670 billion-$10.920 billion to $10.790 billion-$11.040 billion vs $10.773 billion estimate.
EARNINGS | Jul 29, 2026, 08:13 PM UTC
L
BHC Bausch Health Companies Inc RESULTS: Q2, Q2 Net Income $260M, Q2 REV $2.852B, Q2 pretax profit $348M, Q2 Operating Income $740M, Q2 EPS
BHC Bausch Health Companies Inc RESULTS: Q2, Q2 Net Income $260M, Q2 REV $2.852B, Q2 pretax profit $348M, Q2 Operating Income $740M, Q2 EPS $0.68, Q2 ADJ EBITDA $1.075B, Bausch Health Companies Inc Earnings Notes:, Outlo
EARNINGS | Jul 29, 2026, 08:12 PM UTC
L
BHC Beats Q2 EPS, Sales Estimates
BHC reports Q2 EPS and sales above estimates
EARNINGS | Jul 29, 2026, 08:10 PM UTC
L
BHC - BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
BHC - BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
EARNINGS | Jul 29, 2026, 08:06 PM UTC
L
Québec is the first province to list (Pr)OKEDI(MC) (extended-release injectable suspension of risperidone) on the public drug reimbursement
Québec is the first province to list (Pr)OKEDI(MC) (ext
EQUITY | Jul 06, 2026, 11:00 AM UTC